Las endolisinas, una terapia emergente para combatir la resistencia antibiótica: Una revisión sistemática
Autores/as
- Luisa María Aguilar-Jiménez Universidad libre
- Ana Sofía Arango Mendoza Universidad libre
- Diana María Muñoz Pérez Universidad libre
Palabras clave:
Endolisinas, resistencia antibiótica, terapia con fagosResumen
Durante las últimas décadas, la resistencia antimicrobiana de bacterias patógenas (AMR, por sus siglas en inglés) se ha convertido en una de las mayores preocupaciones de la Organización mundial de la salud y es una de las principales causas de mortalidad a nivel mundial. Diferentes investigaciones han encontrado ciertas proteínas con capacidad lítica, podrían funcionar como tratamiento alternativo contra estas bacterias resistentes. Para ampliar el conocimiento sobre este tema, se realizó una revisión sistemática con el objetivo de reconocer las características de las endolisinas, su capacidad antimicrobiana sobre diferentes tipos de patógenos bacterianos y la viabilidad de su uso con fines terapéuticos in vivo. En esta revisión se encontró que las endolisinas tienen un efecto antimicrobiano positivo
Descargas
Referencias
Huemer M, Mairpady Shambat S, Brugger SD, Zinkernagel AS. Antibiotic
resistance and persistence—Implications for human health and treatment
perspectives. EMBO Rep. 2020 Dec 3;21(12).
Vanegas-Múnera JM, Jiménez-Quiceno JN. Antimicrobial resistance in the 21st century: Towards a post-antibiotic era? Vol. 38, Revista Facultad Nacional de Salud Publica. Universidad de Antioquia; 2020.
Watkins RR, Bonomo RA. Overview: Global and Local Impact of Antibiotic Resistance. Vol. 30, Infectious Disease Clinics of North America. W.B. Saunders;2016. p. 313–22.
García Apac C. Resistencia antibiótica en el Perú y América Latina Artículo de revisión. 2012.
Lai WCB, Chen X, Ho MKY, Xia J, Leung SSY. Bacteriophage-derived endolysins to target gram-negative bacteria. Vol. 589, International Journal of Pharmaceutics. Elsevier B.V.; 2020.
Heidary M, Khosravi AD, Khoshnood S, Nasiri MJ, Soleimani S, Goudarzi M.Daptomycin. Vol. 73, Journal of Antimicrobial Chemotherapy. Oxford University Press; 2018. p. 1–11.
Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol. 2006 Feb;44(2):655–6.
Bender JK, Cattoir V, Hegstad K, Sadowy E, Coque TM, Westh H, et al. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a commo nomenclature. Drug Resistance Updates. 2018 Sep 1;40:25–39.
Linden SB, Alreja AB, Nelson DC. Application of bacteriophage-derived endolysins to combat streptococcal disease: current State and perspectives. Vol. 68, Current Opinion in Biotechnology. Elsevier Ltd; 2021. p. 213–20.
Ongenae V, Briegel A, Claessen D. Cell wall deficiency as an escape mechanism from phage infection. Open Biol. 2021 Sep 1;11(9).
Cisek AA, Dąbrowska I, Gregorczyk KP, Wyżewski Z. Phage Therapy in Bacterial, Infections Treatment: One Hundred Years After the Discovery of Bacteriophages. Vol. 74, Current Microbiology. Springer New York LLC; 2017. p. 277–83.63
Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. Molecular
mechanisms of antibiotic resistance. Vol. 13, Nature Reviews Microbiology. Nature Publishing Group; 2015. p. 42–51.
Letrado P, Corsini B, DÍez-Martínez R, Bustamante N, Yuste JE, García P.Bactericidal synergism between antibiotics and phage endolysin Cpl-711 to kill multidrug-resistant pneumococcus. Future Microbiol. 2018 Sep 1;13(11):1215–23.
Wu M, Hu K, Xie Y, Liu Y, Mu D, Guo H, et al. A novel phage PD-6A3, and its endolysin Ply6A3, with extended lytic activity against Acinetobacter baumannii. Front Microbiol. 2019;10(JAN).
Jasim HN, Hafidh RR, Abdulamir AS. Formation of therapeutic phage cocktail and endolysin to highly studymulti-drug resistant acinetobacter baumannii: In vitro and in vivo. Iran J Basic Med Sci. 2018 Nov 1;21(11):1100–8.
Knaack D, Idelevich EA, Schleimer N, Molinaro S, Kriegeskorte A, Peters G, et al. Bactericidal activity of bacteriophage endolysin HY-133 against Staphylococcus aureus in comparison to other antibiotics as determined by minimum bactericidal concentrations and time-kill analysis. Diagn Microbiol Infect Dis. 2019 Apr 1;93(4):362–8.
Coates ARM, Hu Y, Holt J, Yeh P. Antibiotic combination therapy against resistantv bacterial infections: synergy, rejuvenation and resistance reduction. Expert Rev Anti Infect Ther. 2020 Jan 2;18(1):5–15.
Fernández DG, Llamas LF, González AR, Suárez PG. Bacteriophages and endolysins in the food industry. Arbor. 2020;196(795):1–11.
Cahill J, Young R. Phage Lysis: Multiple Genes for Multiple Barriers. In: Advances in Virus Research. Academic Press Inc.; 2019. p. 33–70.
Marques AT, Tanoeiro L, Duarte A, Gonçalves L, Vítor JMB, Vale FF. Genomic analysis of prophages from klebsiella pneumoniae clinical isolates. Microorganisms. 2021 Nov 1;9(11).
Oliveira H, Azeredo J, Lavigne R, Kluskens LD. Bacteriophage endolysins as a response to emerging foodborne pathogens. Vol. 28, Trends in Food Science and Technology. 2012. p. 103–15.
Dong H, Zhu C, Chen J, Ye X, Huang YP. Antibacterial activity of Stenotrophomonas maltophilia endolysin P28 against both gram-positive and gram-negative bacteria. Front Microbiol. 2015;6(NOV).
Zampara A, Sørensen MCH, Grimon D, Antenucci F, Vitt AR, Bortolaia V, et al. Exploiting phage receptor binding proteins to enable endolysins to kill Gramnegative bacteria. Sci Rep. 2020 Dec 1;10(1).
Briers Y, Lavigne R. Breaking barriers: Expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria. Vol. 10, Future Microbiology. Future Medicine Ltd.; 2015. p. 377–90.
Méndez A. Quelantes [Internet]. La guia. 2014 [cited 2022 Jun 8]. Available from: https://quimica.laguia2000.com/quimica-inorganica/quelantes
Oliveira H, Thiagarajan V, Walmagh M, Sillankorva S, Lavigne R, Neves-Petersen MT, et al. A thermostable salmonella phage endolysin, Lys68, with broad bactericidal properties against gram-negative pathogens in presence of weak acids. PLoS One. 2014 Oct 7;9(10).
Joshi H, Jain V. Novel method to rapidly and efficiently lyse Escherichia coli for the isolation of recombinant protein. Anal Biochem. 2017 Jul 1;528:1–6.
Vasina D v., Antonova NP, Grigoriev I v., Yakimakha VS, Lendel AM, Nikiforova
MA, et al. Discovering the Potentials of Four Phage Endolysins to Combat GramNegative Infections. Front Microbiol. 2021 Oct 13;12.
Rehman S, Ali Z, Khan M, Bostan N, Naseem S. The dawn of phage therapy. Vol. 29, Reviews in Medical Virology. John Wiley and Sons Ltd; 2019.
Fernández DG, Llamas LF, González AR, Suárez PG. Bacteriophages and endolysins in the food industry. Arbor. 2020;196(795):1–11.
